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Abstract 
Review on early T-cell precursor acute 
lymphoblastic leukemia, with data on clinics and 
the genes possibly involved. 
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Other names 
Early T-cell precursor lymphoblastic 
leukemia/ETP-ALL/ETP T-ALL 
Clinics and pathology 
Note 
Identified in 2009 from gene expression profiling 
data, Early T cell Precursor Acute Lymphoblastic 
Leukemia (ETP-ALL) represents a subset of T-
ALL sharing transcriptional and immunophenotypic 
similarities with early T-cell precursors (Coustan-
Smith et al., 2009).  
ETP-ALL is currently defined by a distinctive 
phenotype characterized by a lack of expression of 
the T-lineage cell surface markers CD1a and CD8, 
weak or absent expression of CD5 and aberrant 
expression of one or more myeloid or stem cell 
markers (Coustan-Smith et al., 2009).  
Since the description, genetic alterations and 
prognostic data have been reported in literature 
improving our understanding of this subgroup. 
Therefore, ETP-ALL has been included as a 
provisional entity in the 2016 revision of the WHO 
classification of Acute Leukemias (Arber et al., 
2016). 
Disease 
Phenotype/cell stem origin 
Early T-cell precursors (ETPs) are immature 
progenitors that have recently immigrated from the 
bone marrow to the thymus and which retain a 
multilineage differentiation potential (T-lymphoid, 
natural killer, dendritic and myeloid cell 
differentiation potential). Animal model based 
studies of ETPs demonstrate similarities with 
immature myeloid progenitors and hematopoietic 
stem cells (Bell and Bandhoola, 2008; Wada et al., 
2008). Because gene expression profiling is not part 
of routine laboratory investigations, ETP-ALL 
cases are currently identified through the phenotype 
of blast cells : CD1a-, CD8-, CD5- /weak, and 
positivity for one or more stem cell and/or myeloid 
antigens (CD117, CD34, HLA-DR, CD13, CD33, 
CD11b, and/or CD65) (Coustan-Smith et al., 2009; 
Chopra et al., 2014). ETP-ALL typically also 
express CD2, CD7 and cytoplasmic CD3 and may 
express CD4. 
Epidemiology 
Initially described from children ALL cohorts, 
ETP-ALL have also been identified in adults. 
Frequency of ETP-ALL varies among studies 
around 10-15% of T ALL. 
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In children, ETP-ALL has been reported in 11% to 
16% of T-ALL (Coustan-Smith et al., 2009; Patrick 
et al., 2014). 
In adults, ETP-ALL frequency ranges from 7,4% 
(Neumann et al., 2012) to 17% of T-ALL (Jain et 
al., 2016). 
Based on gene expression profiling, some authors 
suggest that there is an immature signature related 
to ETPs (called "near ETP' or "close to ETP") 
which may be more prevalent (Van Vlierberghe et 
al., 2013; Haydu and Ferrando, 2013). 
Clinics 
Most studies report no significant association 
between ETP-ALL signature and clinical features 
including sex, age, white blood cell count, and 
central nervous system involvement (Coustan-
Smith et al., 2009; Inukai et al., 2012; Neumann et 
al., 2012).  
Though, two no recurrent features were identified : 
an older age in paediatric population (Coustan-
Smith et al., 2009) and a lower frequency of 
mediastinal mass at diagnosis in adult population 
(Neumann et al., 2012). 
Cytology 
No specific morphologic features have been 
reported to date. 
Treatment 
Since there is no consensus on the prognosis (see 
below), no specific protocol is recommended. 
Because of the trend to negative impact on 
prognosis, some authors suggest that new 
therapeutic strategies are needed to improve the 
outcomes of ETP-ALL (Jain et al., 2016; Neumann 
et al., 2013), including the use myeloid-targeted 
therapies such as tyrosine kinase inhibitors 
(Neumann et al., 2012; Neumann et al., 2013; 
Zhang et al., 2012) 
Prognosis 
There is currently no consensus on the prognosis of 
ETP-ALL. 
Initial prognostic studies between 2009 and 2012 
reported a negative prognostic impact on response 
rate and survival (Coustan-Smith et al., 2009, 
Inukai et al., 2012; Ma et al., 2012) and a higher 
risk of relapse (Allen and al., 2013). 
These data were not confirmed in more recent 
studies with larger cohorts (Brent et al., 2014; 
Patrick et al., 2014; Zuurbier et al., 2014). 
However, in 2016, a MD Anderson study reported 
again a negative prognostic impact on the response 
rate and the overall survival of patients with ETP-
ALL (Jain et al., 2016). 
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Cytogenetics 
No specific cytogenetic abnormality is associated 
with ETP-ALL subtype.  
In most studies, ETP-ALL patients present highly 
variable karyotypes with remarkably a lower 
frequency of classic recurrent rearrangements 
associated with T-ALL (Patrick et al., 2014).  
Coustan Smith and al reported a higher frequency 
of deletion 13q (Coustan-Smith et al., 2009) and 
Patrick et al a higher frequency of KMT2A 
rearrangements (Patrick et al., 2014).  
SNP analysis demonstrated a higher frequency of 
copy number alterations in ETP-ALL vs non ETP-
ALL (Coustan-Smith et al., 2009). 
Genes involved and 
proteins 
ETP-ALL subgroup is characterized by a high 
genetic heterogeneity and present a distinct 
genomic profile defined by a lower incidence of 
typical mutations associated with T ALL such as 
NOTCH1 or FBXW7 and a high frequency of 
myeloid associated gene mutations ( FLT3, RAS 
mutations, DNMT3A, IDH1 / IDH2 mutations) 
(Neumann et al., 2013; Van Vlierberghe et al., 
2011; Zhang et al., 2012).  
Whole exome and whole genome sequencing 
approaches identified mutations in multiple 
pathways including mutations in genes activating 
cytokine receptor and RAS signalling ( NRAS , 
KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 and 
BRAF), inactivating haematopoietic transcription 
factors ( GATA3, ETV6, RUNX1, IKZF1 and 
EP300) and in epigenetic regulators (EZH2, EED, 
SUZ12, SETD2 and EP300) (Zhang et al., 2012) 
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